/PRNewswire/ IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today announced it has raised $23 million in Series A.
Partial exercise of the Over-Allotment Option through the issuance of 314,055 new shares, amounting to approximately €4.2m Definitive size of the offering increased to approximately €35.7m Regulatory
MaaT Pharma becomes the first company developing microbiome-based drugs to be listed on the regulated market of Euronext Paris Capital increase of €31.5m and which could be increased to €36.2m
Capital increase of 2,333,333 new ordinary shares (corresponding, on an indicative basis, to an amount of approximately €35.0 m1) which may be increased to a maximum of 3,085,831 ordinary new shares